Longboard Pharmaceuticals, Inc. (LBPH) Misses Q3 EPS by 5c Nov 7, 2024 04:13PM
B.Riley Downgrades Longboard Pharmaceuticals Inc (LBPH) to Neutral Oct 14, 2024 09:02AM
Longboard Pharmaceuticals (LBPH) Acquired by Lundbeck for $60/sh or $2.6B Deal Oct 14, 2024 06:30AM
Longboard Pharmaceuticals (LBPH) Initiates Phase 3 DEEp SEA Study of Bexicaserin Sep 26, 2024 08:33AM
Longboard Pharmaceuticals (LBPH) Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome Sep 19, 2024 08:32AM


Sep 18, 2024 06:38AM Longboard Pharmaceuticals Inc (LBPH) PT Raised to $80 at H.C. Wainwright
Sep 17, 2024 06:21AM Baird Reiterates Outperform Rating on Longboard Pharmaceuticals Inc (LBPH)
Sep 10, 2024 06:07AM Truist Securities Starts Longboard Pharmaceuticals Inc (LBPH) at Buy
Sep 9, 2024 06:24AM Baird Reiterates Outperform Rating on Longboard Pharmaceuticals Inc (LBPH)
Sep 9, 2024 06:13AM Longboard Pharmaceuticals (LBPH) Reports Positive Interim Analysis Results from the Open-Label Extension of the Phase 1b/2a PACIFIC Study
Sep 6, 2024 07:10AM Baird Reiterates Outperform Rating on Longboard Pharmaceuticals Inc (LBPH)
Aug 1, 2024 04:13PM Longboard Pharmaceuticals, Inc. (LBPH) Misses Q2 EPS by 12c
Jul 11, 2024 06:56AM Longboard Pharmaceuticals Inc (LBPH) PT Raised to $60 at Baird
Jul 2, 2024 02:13PM Longboard Pharmaceuticals Inc (LBPH) PT Raised to $45 at Citi
Jun 11, 2024 05:37AM Citi Reiterates Buy Rating on Longboard Pharmaceuticals Inc (LBPH)
Jun 10, 2024 04:21PM Longboard Pharmaceuticals Inc (LBPH) PT Raised to $36 at B.Riley
Jun 10, 2024 09:01AM Longboard Pharmaceuticals (LBPH) Announces Positive Interim Results from OLE of Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies